Okey Stephanie 4

What Happened

• Stephanie Okey, a director of Crinetics Pharmaceuticals (CRNX), received awards on 2026-06-18 totaling 15,655 units: 5,925 shares (reported as award) and 9,730 derivative awards (reported as an award/derivative). Each line shows an acquisition price of $0, so the Form 4 records $0 cash paid — these are compensation grants, not open-market purchases.
• The grants are subject to vesting conditions described in the filing: the 5,925 award is reported as restricted stock units (RSUs) that convert to shares, and the 9,730 award is a derivative award (stock option-like). Combined immediate cash value is $0 on the Form 4 because they were granted as compensation.

Key Details

• Transaction date: 2026-06-18; Form 4 filed 2026-06-22 (filed within the SEC’s 2-business-day window).
• Awards: 5,925 RSUs (F1) and 9,730 derivative awards (F2), total 15,655 units; acquisition price $0.00.
• Vesting: F1 — RSUs vest 100% on the earlier of (a) first anniversary of grant or (b) next annual meeting, subject to continued board service. F2 — stock option/derivative vests/becomes exercisable on the earlier of (a) first anniversary or (b) next annual meeting, subject to continued board service.
• Shares owned after transaction: not specified in the information provided (check the full filing for post-transaction holdings).
• No 10b5-1 plan, sale, tax-withholding, or late-filing indicators noted in the provided data.

Context

• These are compensation awards to a director (not an open-market buy or sell). Grants at $0 are common for RSUs/options and reflect equity compensation rather than a purchase price.
• For the derivative award (F2), vesting makes the security exercisable later; this is not an immediate sale or cashless exercise. Such grants are routine for board members to align incentives with shareholders but do not by themselves indicate the director is buying or selling stock.